Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revlimid in recurrent ovarian cancer
NCT01111903Phase 2Completed
- Sponsor
- ARCAGY
- Start
- May 2009
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lenalidomide in ovarian cancer, sponsored by ARCAGY. Primary endpoint: Clinical Benefit Rate at 4 months. Started May 2009; status: completed.
02
Drugs
lenalidomide
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT01111903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01111903.